54
Participants
Start Date
October 8, 2020
Primary Completion Date
November 10, 2023
Study Completion Date
November 10, 2023
Ipatasertib
Ipatasertib administered orally (400 mg) once a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Capecitabine
Capecitabine administered orally (1000 mg/m2) twice a day, from day 1 to day 14, and rest from day 15 to day 21 of every 21-day cycle
Eribulin
Eribulin 1.23 mg/m2 administered intravenously Days 1 and 8 of every 21-day cycle
Carboplatin
Carboplatin AUC5 administered intravenously day 1 of every 21-day cycle
Gemcitabine
Gemcitabine administered intravenously (1000 mg/m2) at days 1 and 8 of every 21-day cycle
Hospital San Pedro de Alcántara, Cáceres
Hospital Provincial de Castellón, Castellon
Hospital Universitari Arnau de Vilanova, Lleida
Hospital Quiron San Camilo- Ruber Juan Bravo, Madrid
Hospital Universitario Ramón y Cajal, Madrid
Hospital Universitario Virgen de la Victoria, Málaga
Hospital Clínico Universitario Virgen de la Arrixaca, El Palmar
Hospital Clínico Universitario de Valencia, Valencia
Hospital Arnau de Vilanova, Valencia
Hospital Universitario Miguel Servet, Zaragoza
Champalimaud Clinical Centre - Champalimaud Foundation, Lisbon
Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto), Porto
Hospital del Mar, Barcelona
Hospital Universitari Dexeus, Barcelona
Hoffmann-La Roche
INDUSTRY
MedSIR
OTHER